Fig. 3From: Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE studyMean MSTAQ scores for patient treatment adherence at baseline and Week 26. *p < 0.05; **p = 0.0006. DMT, disease-modifying therapy; MSTAQ, Multiple Sclerosis Treatment Adherence QuestionnaireBack to article page